

| Catalog No. | MB613013 | ||||
|---|---|---|---|---|---|
| Description |
Anti-Mouse CD223/LAG3 Nanobody (SAA0767) [SAA0767] (MB613013) is a alpaca monoclonal antibody detecting CD223 in ELISA, FCM. Suitable for Mouse.
Highlights
|
||||
| Species reactivity | Mouse | ||||
| Applications | ELISA, FCM | ||||
| Host species | Alpaca | ||||
| Isotype | VHH-8His-Cys-tag | ||||
| Clone ID | SAA0767 | ||||
| Clonality | Monoclonal | ||||
| Target | FDC, LAG3, Lymphocyte activation gene 3 protein, CD223, sLAG-3, LAG-3, FMD30410 | ||||
| Endotoxin level | Please contact with the lab for this information. | ||||
| Purity | >95% as determined by SDS-PAGE. | ||||
| Purification | Purified by Nickel column. | ||||
| Accession | Q61790 | ||||
| Form | Liquid | ||||
| Storage buffer | 0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
||||
| Product Usage Information |
| ||||
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. | ||||
| Background | Lymphocyte activation gene 3 protein (CD223/LAG3) is a ~56 kDa protein. Inhibitory receptor on antigen activated T-cells. Delivers inhibitory signals upon binding to ligands, such as MHC class II, its main ligand present at the surface of antigen-presenting cells (APCs), and FGL1, which is secreted by hepatocytes and certain types of tumor cells. Ligand-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation. Mechanistically, ligand-binding promotes (1) ubiquitination of the KIEELE motif, unleashing the RRFSALE motif from the membrane and (2) leading to the formation of condensates with the TCR component CD3E, thereby disrupting the association between CD3E and LCK and preventing TCR activation. May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1. CD223 is the therapeutic target of relatlimab (Opdualag). 1. Workman, CJ. et al. (2002) European journal of immunology 32, 2255-63. PMID: 12209638 2. Workman, CJ. et al. (2002) Journal of immunology (Baltimore, Md. : 1950) 169, 5392-5. PMID: 12421911 3. Workman, CJ. et al. (2003) European journal of immunology 33, 970-9. PMID: 12672063 4. Workman, CJ. et al. (2004) Journal of immunology (Baltimore, Md. : 1950) 172, 5450-5. PMID: 15100286 5. Workman, CJ. et al. (2005) Journal of immunology (Baltimore, Md. : 1950) 174, 688-95. PMID: 15634887 6. Wang, J. et al. (2019) Cell 176, 334-347.e12. PMID: 30580966 7. Maruhashi, T. et al. (2022) Immunity 55, 912-924.e8. PMID: 35413245 8. Ming, Q. et al. (2022) Nature immunology 23, 1031-1041. PMID: 35761082 9. Silberstein, JL. et al. (2024) Proceedings of the National Academy of Sciences of the United States of America 121, e2310866121. PMID: 38483996 10. Ming, Q. et al. (2024) Nature communications 15, 7513. PMID: 39209860 | ||||
| Note | For research use only. |

SDS-PAGE for Anti-Mouse CD223/LAG3 Nanobody (SAA0767)




Contact us for custom quotes, bulk requests and any other issues.
Mail: support@abinScience.com


+86-27-87433958
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский